# Pizarra — PT-pseudo_11fe9c6ca833 (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_11fe9c6ca833
Task: 1

Encounter: Urology - outpatient on 02 Feb 2025.
Referrer: Dr. E. Mulder (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 66-year-old male
  - PSA: 190.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 4.097 ng/mL²
  - PSA velocity: 41.57 ng/mL/yr
  - Prior PSA: 125.1 ng/mL
  - Prostate volume: 46.38 mL
  - Months since last PSA: 2
  - DRE findings: Nodus (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.9718793 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypertension, Coronary artery disease
  - Problem list / PMHx: Hypertension, Coronary artery disease
  - Current medication: valsartan, lisinopril, metoprolol, aspirin 80 mg
  - Allergies: NKA
  - Additional notes: PSA 190 ng/mL. PI-RADS 5. PSAD 4.10. Prostate volume 46 mL. DRE nodus. csPCa 0.97.

Vitals: weight 61 kg, height 167 cm, BMI 21.9, BP 125/89 mmHg, HR 77 bpm. Smoking: Ex-smoker (10 pack-yr, quit 2022).

Chief complaint: Clinical attention was requested due to a prostate-specific antigen measurement of 190.0 ng/mL and a prior biopsy-proven prostate cancer.

History: A 66-year-old civil engineer resides with his partner, balancing a biweekly tennis regimen with moderate alcohol intake. Clinical consultation was sought to reassess a previously established prostate malignancy following a positive prior biopsy, now accompanied by a prostate-specific antigen level of 190.0 ng/mL. Urinary complaints include an IPSS score of 14/35, driven mainly by nocturia and a diminished stream, though hematuria and acute retention are absent. Systemic history encompasses hypertension and coronary artery disease, stabilized during his most recent cardiology visit, and managed pharmacologically with valsartan, lisinopril, metoprolol, and aspirin 80 mg. Tobacco use ceased in 2022 after a cumulative 10 pack-year exposure. A recent chest radiograph showed no abnormalities. Commuting over an hour via rail, he specifically requested extended consultation time.

Physical examination: DRE — texture: firm with an irregular nodule situated in the left peripheral zone, while the surrounding tissue remains symmetrically enlarged yet non-tender. General vitals show a blood pressure of 125/89 mmHg alongside a regular cardiac rhythm at 77 beats per minute. Peripheral lymph nodes and abdominal organs reveal no enlargement or masses.

Patient info: civil engineer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Tennis 2x/week; IPSS score: 14/35 (moderate LUTS).

Recent other appointments: Radiology — chest X-ray (routine).
Admin: Patient travels 60+ min by train to clinic; allow buffer.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.53 +/- 0.27   (95% CI 0.05-0.97)

Where the uncertainty comes from:
  - aleatoric  dA = 0.25  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.08  (few labelled cases resemble this one)
  - 0.9 effective neighbours out of 10; 1 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {no, yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=190.0, age=66.0, psad=4.097, dre_ord=1.0, vol=46.38, n_pmhx=2.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only considered structured variables (PI-RADS=5, PSA=190.0, PSA density=4.097, Age=66, DRE=Nodus, Volume=46.38, N_pmhx=2.0) and failed to incorporate the critical context that the patient has a *prior positive biopsy*. It also ignored the PSA velocity (41.57 ng/mL/yr) and the specific clinical context of the prior diagnosis.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested biopsy based on a 53% probability, but the guideline criterion explicitly states the decision is undetermined by the visible panel. The prior fails to account for the fact that the prior positive biopsy changes the question from "does he have cancer" to "is the existing cancer stable/progressing/requiring re-staging." The prior's uncertainty interval (0.05-0.97) is too wide, masking the clinical ambiguity highlighted by the protocol expert.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - does the lesion compare with a previous MRI?
PSA history - trend / velocity beyond the headline value
previous GP / urology notes - details on the prior positive biopsy result
laboratory panel - full panel
family-history anamnesis

GUIDELINE ANCHOR
The guideline states that the decision must come from retrieved documents, specifically whether the prior grade is documented, whether the lesion changed against a previous MRI, and whether surveillance re-biopsy is due.

## [5] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
{"case_id": "PT-pseudo_11fe9c6ca833", "radiology_report": "Subject: Multiparametric MRI of the Prostate\nReporting Facility: Spaarne Gasthuis, Haarlem\nExamination Date: 28 January 2025\n\nClinical Indication:\nRe-assessment prompted by a markedly elevated PSA measurement of 190.0 and a history of a positive biopsy.\n\nFINDINGS:\nGlandular volume registers at 46.38 mL. T2-weighted sequences highlight a sharply demarcated, profoundly hypointense area spanning roughly 28 x 22 x 20 mm within the left peripheral zone at the base and mid-gland. Diffusion-weighted imaging shows intense signal restriction paired with correspondingly low apparent diffusion coefficient readings. Dynamic contrast studies capture early, focal enhancement confined to this region. Neither extraprostatic extension nor seminal vesicle invasion is evident.\n\nIMPRESSION:\nPI-RADS 5 lesion located in the left peripheral zone.\nProstate volume 46.38 mL; PSA density 4.097 ng/mL/mL.\ncsPCa predicted probability 0.9718793."}
get_psa_trend
{"case_id": "PT-pseudo_11fe9c6ca833", "psa_trend": [{"date": "Dec 2023", "val": 15.3}, {"date": "Apr 2024", "val": 3.3}, {"date": "Sep 2024", "val": 19.1}, {"date": "Feb 2025", "val": 190.0}]}
get_previous_notes
{"case_id": "PT-pseudo_11fe9c6ca833", "previous_notes": [{"date": "12 Aug 2023", "author": "Dr. E. Mulder (GP)", "text": "Early 2023 screening yielded a PSA of 38 ng/mL, which climbed to 86.0 ng/mL by December 2023. This steep trajectory in a 66-year-old individual necessitated an urgent urology referral to initiate mpMRI planning and comprehensive evaluation."}]}
get_lab_results
{"case_id": "PT-pseudo_11fe9c6ca833", "laboratory_results": [{"name": "PSA", "val": "190.0 ng/mL", "date": "21 Dec 2024", "flag": "H"}, {"name": "Free PSA", "val": "31.26 ng/mL", "date": "21 Dec 2024", "flag": ""}, {"name": "%Free PSA", "val": "16%", "date": "21 Dec 2024", "flag": "L"}, {"name": "Haemoglobin", "val": "17.9 g/dL", "date": "21 Dec 2024", "flag": ""}, {"name": "WBC", "val": "3.5 x10^9/L", "date": "21 Dec 2024", "flag": ""}, {"name": "Platelets", "val": "217 x10^9/L", "date": "21 Dec 2024", "flag": ""}, {"name": "Creatinine", "val": "87 umol/L", "date": "21 Dec 2024", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "21 Dec 2024", "flag": ""}, {"name": "Testosterone", "val": "12.9 nmol/L", "date": "21 Dec 2024", "flag": ""}, {"name": "Alkaline phosphatase", "val": "65 U/L", "date": "21 Dec 2024", "flag": ""}, {"name": "LDH", "val": "173 U/L", "date": "21 Dec 2024", "flag": ""}, {"name": "HbA1c", "val": "5.9 %", "date": "21 Dec 2024", "flag": ""}]}

NOT RETRIEVED
The pathology report was not retrieved, which is the only document that could explicitly state the ISUP grade or Gleason score of the prior cancer.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- MRI report: PI-RADS 5 lesion located in the left peripheral zone.
- PSA trend: Rising velocity of 41.57 ng/mL/yr, culminating in a PSA of 190.0 ng/mL.

AGAINST sampling this patient now:
- Previous notes: No information regarding the prior biopsy result (grade or outcome).

WHERE THIS LEANS
The high-risk MRI finding combined with a rapidly rising PSA strongly suggests that further tissue characterization is warranted to guide management, despite the lack of prior grade information.

[Sections actually revealed in this consultation: radiology_report, psa_trend, previous_notes, laboratory_results. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [6] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [7] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: uncertain)

Although the patient has a prior positive biopsy, the rapidly rising PSA (190.0 ng/mL) and the PI-RADS 5 finding on the mpMRI suggest that further tissue characterization is necessary to guide management. The prior notes failed to document the prior biopsy grade, which is the key missing piece of information needed to determine if the existing cancer is stable or progressing. Therefore, sampling is recommended to establish a current pathological baseline.

Variables that carried weight: bx=important, age=important, dre=noted, psa=decisive, vol=noted, psad=important, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes, laboratory_results
